Organon & Co. — Form 10-Q
Filed October 30, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 22/100
What the filing says
Organon amended its Development and Commercialization Agreement with Samsung Bioepis (Amendment No. 11, effective September 11, 2026) to add three new dosage forms of the SB17 Product in Canada; specific financial terms and product criteria are redacted as commercially sensitive. Separately, Organon amended its Executive Change in Control Severance Program (effective August 14, 2026) to clarify benefit calculations, including minimum severance multiples (2.0x for Section 16 officers, 1.25x for others) and enhanced protections for former Merck employees with 16+ years continuous service.
Why this rating
Samsung partnership amendment is routine product-scope extension with confidential economics. Severance plan restatement is administrative clarification of existing change-of-control protections. Neither materially alters business trajectory or financials relative to $2.5B market cap.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.